MET and cancer: The activation of c‐Met is associated with chemoresistance in several types of cancer (Huang et al., 2016; Li et al., 2016) and participates in conferring the resistance to molecular targeted therapies (Firtina Karagonlar et al., 2016; Gou et al., 2016; Heynen et al., 2014; Kogita et al., 2015; Phan et al., 2015; Wilson et al., 2012).